Jump to page content

Translation-Hub Organoids and Cell-Engineering

The Organoids and Cell Engineering hub aims to harness new approaches in genetic engineering (e.g. CRISPR/Cas) or cell breeding, stem cell technology and bioprinting (e.g. organoids, human-on-achip models) to facilitate precision medicine through the development of new human models for preclinical research and the methodical development of cell-based therapies. This includes the use and improvement of new 2D and 3D cell culture models such as organoid, human-on-a-chip or mini-organ models. Human cells and their genetically edited forms can be examined under almost physiological conditions for a variety of enquiries, for example, regarding functional characteristics or processes of vascularization.

For the analysis of these models, the hub uses a range of microscopy methods (e.g. light-sheet microscopy, high-content microscopy and quantitative image analysis) and single cell analyses in cooperation with the Multi-Omics hub and the Focus Area Single Cell Approaches for Personalized Medicine. On the other hand, the activities of the hub include the use of genome engineering methods (e.g. using CRISPR/Cas) and the further development of approaches to generate human CAR T cells for cancer immunotherapy or to correct mutations in patient cells (primary cells or adult stem cells).

Steering Committee
Name Affiliation
Dr. Sebastian Diecke MDC
Dr. Mina Gouti MDC
Prof. Dr. Andreas Hocke Charité
Prof. Dr. Igor Sauer Charité
Prof. Dr. Simone Spuler Charité, MDC
Dr. Harald Stachelscheid BIH, Charité
Dr. Sophie Van Linthout Charité


  • Dr. Christian Gallus

    Project Lead National Strategy for Gene and Cell Based Therapies

    Contact information
    Phone:+49 30 450 543 314
  • Dr. Doris Meder

    Head of Strategic Science Management

    Contact information
    Phone:+49 30 450 543 045